Physician profile
Robin Butcher
NPI 1982330288
$17,568.29
in general payments reported to CMS, 2019-2025
39 companies · $6,156 in 2025
The $6,156 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $455 · 2023: $5,903 · 2024: $5,054 · 2025: $6,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Travel and Lodging: $1,514 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,582.80 |
| Travel and Lodging | $1,513.87 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,184.25 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Novo Nordisk INC | $1,699.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,525.68 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,137.16 | 2022-2025 | |
| Dexcom, INC. | $1,105.82 | 2023-2025 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $1,029.68 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $760.76 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $733.05 | 2022-2025 | Korlym |
| Amgen INC. | $626.52 | 2022-2025 | Evenity, Tepezza, Prolia |
| Mannkind Corporation | $600.69 | 2022-2025 | Afrezza |
| Sequel Med Tech, LLC | $573.55 | 2025 | Twiist |
| Radius Health, INC. | $555.50 | 2022-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $517.59 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $488.24 | 2023-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $476.28 | 2022-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.65 | 2022-2024 | Farxiga |
| Recordati_rare_diseases_inc. | $325.15 | 2023-2025 | Signifor Lar, Isturisa |
| Kyowa Kirin, INC. | $282.47 | 2023-2025 | Crysvita |
| Insulet Corporation | $235.49 | 2025 | Omnipod |
| Abbvie INC. | $225.04 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $202.03 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $194.85 | 2023 | |
| Madrigal Pharmaceuticals | $120.50 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $79.80 | 2023 | Tlando, Xyosted, Nocdurna |
| Alexion Pharmaceuticals, INC. | $70.29 | 2023-2025 | Strensiq |
| Soleno Therapeutics, INC. | $49.22 | 2025 | Vykat Xr |
| Almatica Pharma LLC | $46.21 | 2024 | Teriparatide |
| Tolmar, INC. | $41.83 | 2023 | |
| Averitas Pharma INC. | $41.31 | 2023-2025 | Qutenza |
| Esperion Therapeutics, INC. | $29.94 | 2024-2025 | Nexletol |
| Neurocrine Biosciences, INC. | $25.22 | 2024 | |
| Amarin Pharma, INC. | $21.61 | 2023 | |
| Chiesi USA, INC. | $21.52 | 2024 | Mycapssa |
| Halozyme INC | $21.18 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $20.93 | 2025 | |
| Glaxosmithkline, LLC. | $20.84 | 2025 | Arexvy, Shingrix |
| Rgh Enterprises LLC | $18.53 | 2025 | |
| Pfizer INC. | $14.63 | 2025 | |
| Beta Bionics, INC. | $6.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Butcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.